Latest Advances

  • Condition: Camurati-Engelmann Disease (CED)/Osteoporosis
  • Journal: Modern rheumatology case reports
  • Treatment Used: Denosumab Therapy After Alendronate Treatment
  • Number of Patients: 1
  • Published —
This article reviewed the case of a patient with Camurati-Engelmann disease (genetic disorder that causes characteristic anomalies in the skeleton; CED) and osteoporosis (causes bones to become weak and brittle) treated with denosumab therapy after alendronate treatment.
Showing 1-1 of 1